BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. DISCUSSION: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.
BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. DISCUSSION: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.
Authors: Veronique Dieras; Simona Pop; Frederique Berger; Marie-Eglantine Dujaric; Philippe Beuzeboc; Laurence Escalup; François Clement Bidard; Paul Henri Cottu; Christophe LE Tourneau; Sophie Piperno-Neumann; Valerie Laurence; Mathieu Robain; Bernard Asselain; Jean-Yves Pierga Journal: Anticancer Res Date: 2017-03 Impact factor: 2.480
Authors: Antonio Llombart-Cussac; Xavier Pivot; Laura Biganzoli; Hernan Cortes-Funes; Kathleen I Pritchard; Jean-Yves Pierga; Ian Smith; Christoph Thomssen; Stefanie Srock; Miguel Sampayo; Javier Cortes Journal: Breast Date: 2014-07-19 Impact factor: 4.380
Authors: Mario Giuliano; Francesco Schettini; Carla Rognoni; Manuela Milani; Guy Jerusalem; Thomas Bachelot; Michelino De Laurentiis; Guglielmo Thomas; Pietro De Placido; Grazia Arpino; Sabino De Placido; Massimo Cristofanilli; Antonio Giordano; Fabio Puglisi; Barbara Pistilli; Aleix Prat; Lucia Del Mastro; Sergio Venturini; Daniele Generali Journal: Lancet Oncol Date: 2019-09-04 Impact factor: 41.316
Authors: H S Rugo; R S Finn; V Diéras; J Ettl; O Lipatov; A A Joy; N Harbeck; A Castrellon; S Iyer; D R Lu; A Mori; E R Gauthier; C Huang Bartlett; K A Gelmon; D J Slamon Journal: Breast Cancer Res Treat Date: 2019-01-10 Impact factor: 4.872